0RFI.L - BRAIN Biotech AG

LSE - LSE Delayed price. Currency in EUR
5.26
-0.64 (-10.85%)
As of 04:38PM BST. Market open.
Stock chart is not supported by your current browser
Previous close5.90
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume67,635
Avg. volume3,765
Market cap951,612
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy

    EQS-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year ReportBRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy 25.05.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy H1 ‘22/23 growth +16.8%, +8.2% organic Cash position a solid € 9.2 million Full ownership of core asset Biocatalysts Ltd achi

  • EQS Group

    BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy

    EQS-News: BRAIN Biotech AG / Key word(s): Mergers & Acquisitions/Strategic Company DecisionBRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy 24.05.2023 / 09:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy BRAIN Biotech bought the two remaining minority stakes in Biocatalysts Ltd Trans

  • EQS Group

    Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG

    EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGMResolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG 08.03.2023 / 17:20 CET/CESTThe issuer is solely responsible for the content of this announcement.Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG Executive Board and Supervisory Board discharged with large majority Large majorities in the re-election of one member to the Supervisory Board and the elec

  • Simply Wall St.

    BRAIN Biotech First Quarter 2023 Earnings: €0.12 loss per share (vs €0.11 loss in 1Q 2022)

    BRAIN Biotech ( ETR:BNN ) First Quarter 2023 Results Key Financial Results Revenue: €14.1m (up 36% from 1Q 2022). Net...

  • EQS Group

    Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion

    EQS-News: BRAIN Biotech AG / Key word(s): Capital Markets DayCapital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion 27.02.2023 / 16:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion Strategy: building a successful international multi-niche enzyme and food ingredients champion Performance

  • EQS Group

    BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting

    EQS-News: BRAIN Biotech AG / Key word(s): Quarter Results/Quarterly / Interim StatementBRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting 27.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting Total group revenues plus 35%, organic plus 19% Both segments contribute with double digit organic growth Cash on-hand improvedZwingenberg, Germany, 27. February 2023 –

  • EQS Group

    BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

    EQS-News: BRAIN Biotech AG / Key word(s): AgreementBRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment 22.02.2023 / 14:00 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatmentZwingenberg (Germany), 22 February, 2023 – BRAIN Biotech AG, industrial biotechnology and enzyme expert, toda

  • EQS Group

    BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères

    BRAIN Biotech AG / Key word(s): Strategic Company DecisionBRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères10-Feb-2023 / 11:04 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette FrèresZwingenberg, GermanyF

  • EQS Group

    BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment

    EQS-News: BRAIN Biotech AG / Key word(s): Annual Results/Annual ReportBRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment 16.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment Group sales grew by 29% Total operating performance exceeds for the first time 50 million euros Both business seg

  • EQS Group

    BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform

    EQS-News: BRAIN Biotech AG / Key word(s): Strategic Company DecisionBRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform 10.01.2023 / 12:15 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform Mode of action suited for applications

  • EQS Group

    BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)

    BRAIN Biotech AG / Key word(s): Strategic Company DecisionBRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)10-Jan-2023 / 12:10 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: prioritizing development of therapeutic applica

  • EQS Group

    BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site

    EQS-News: BRAIN Biotech AG / Key word(s): PersonnelBRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site 09.01.2023 / 12:10 CET/CESTThe issuer is solely responsible for the content of this announcement.Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site Dr. Alexander Pelzer appointed as new Head of Research & Development, BRAIN Biotech Zwingenberg site Dr. Martin Langer takes on additional responsibility as Managing Director BioScience Operations, Zwin

  • EQS Group

    BRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG

    EQS-News: BRAIN Biotech AG / Key word(s): MiscellaneousBRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG 17.11.2022 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG Block transaction recently successfully closed MP Beteiligungs-GmbH has increased its holding throughout 2022 Long-term supporter of the development of BRAIN Biotech AGZwingenberg, November 17, 2022 – BRAIN Biotech A

  • EQS Group

    BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides

    EQS-News: BRAIN Biotech AG / Key word(s): AllianceBRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides 25.10.2022 / 09:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharidesZwingenberg, Germany and Charlottesville, VA, USA, 25 October 2022 – BRAIN Biotech AG, a leading European industrial biotechnology specialist, and rare sugars expert Bo

  • EQS Group

    Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand

    EQS-News: BRAIN Biotech AG / Key word(s): Personnel/Strategic Company DecisionChange in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand 27.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Lukas Linnig stepping down as CFO. Michael Schneiders to become new CFO of BRAIN Biotech AG as of October 1st, 2022 Lukas Linnig and Dr. Michael Krohn to jointly lead Akribion Genomics activ

  • EQS Group

    BRAIN Biotech AG sells subsidiary L.A. Schmitt to a URI group company

    EQS-News: BRAIN Biotech AG / Key word(s): Disposal/Strategic Company DecisionBRAIN Biotech AG sells subsidiary L.A. Schmitt to a URI group company 26.09.2022 / 17:20 CET/CESTThe issuer is solely responsible for the content of this announcement. BRAIN Biotech AG further focusses business activities Transaction closed on September 26, 2022 URI group expands its network into European production Zwingenberg, September 26, 2022 – BRAIN Biotech AG has announced the sale of its subsidiary L.A. Schmitt

  • EQS Group

    BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting

    DGAP-News: BRAIN Biotech AG / Key word(s): Quarter Results/Quarterly / Interim StatementBRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting 29.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting Positive topline growth trend confirmed by 29% expansion in Q3 9M Operating cash flow improved significantly from last year On track to reach full financ

  • EQS Group

    BRAIN Biotech publishes first ESG and Sustainability Report

    DGAP-News: BRAIN Biotech AG / Key word(s): SustainabilityBRAIN Biotech publishes first ESG and Sustainability Report 20.06.2022 / 08:00 The issuer is solely responsible for the content of this announcement.BRAIN Biotech publishes first ESG and Sustainability ReportZwingenberg, June 20, 2022 – BRAIN Biotech AG has published its first ESG and sustainability report. The company, which already directly addresses at least five UN Sustainable Development Goals (SDGs) with its products and solutions, s